Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618718 | 0.89 | KMT2A (0.62) | KMT2AMAPK1MAPTMEN1GRM5 | |
| SCHEMBL6668269 | 0.85 | KMT2A (0.60) | KMT2AMAPK1MAPTMEN1P2RX7 | |
| SCHEMBL6668267 | 0.85 | KMT2A (0.60) | KMT2AMAPK1MAPTMEN1P2RX7 | |
| SCHEMBL5619675 | 0.83 | KMT2A (0.65) | KMT2AMAPK1MAPTPOLBLMNA | |
| SCHEMBL4712567 | 0.83 | KMT2A (0.77) | KMT2AMAPK1MAPTALOX15GRM5 | |
| SCHEMBL4712562 | 0.83 | KMT2A (0.77) | KMT2AMAPK1MAPTALOX15GRM5 | |
| SCHEMBL4712565 | 0.83 | KMT2A (0.77) | KMT2AMAPK1MAPTALOX15GRM5 | |
| SCHEMBL1713614 | 0.82 | KMT2A (1.00) | KMT2AMAPK1MAPTPOLBALOX15 | |
| SCHEMBL523698 | 0.82 | KMT2A (1.00) | KMT2AMAPK1MAPTPOLBALOX15 | |
| SCHEMBL739575 | 0.82 | KMT2A (1.00) | KMT2AMAPK1MAPTPOLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | KMT2A 3440/4885MAPK1 544/4885MAPT 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.